We serve 1-(2-Methoxyphenyl)piperazine CAS:35386-24-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(2-Methoxyphenyl)piperazine
CAS.NO:35386-24-4
Molecular Formula: C11H16N2O
Molecular Weight: 192.25800
Synonyms:
2-MPP
2-(1-Piperazinyl)anisole
Physical and Chemical Properties:
Density: 1.095 g / mL at 25 ° C (lit.)
Boiling point: 130-133 ° C0.1 mm Hg (lit.)
Melting point: 35-40 ° C (lit.)
Flash point:> 230 ° F
Refractive index: n20 / D 1.575 (lit.)
Specification:
Appearance:Slightly yellowish liquid
Purity:≥99.0%
Moisture Content: 0.25%
Impurity: 0.3%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:Intermediate of Naftopidil.
Contact us for information like tert-butyl N-[(2-methylpropan-2-yl)oxycarbonylcarbamothioyl]carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(1-Piperazinyl)anisole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,N’-di-(tert-butoxycarbonyl)thiourea Use and application,2-(1-Piperazinyl)anisole technical grade,usp/ep/jp grade.
Related News: The death toll in China rose to at least 304.1-[4-[2-(diethylamino)ethoxy]phenyl]-1,2-diphenylethanol manufacturer If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such.5-Methoxy-1-[4-(Trifluoromethyl)Phenyl]-1-Pentanone supplier The patient, who arrived from Wuhan, is “stable and under medical care,” the ministry said in a statement, adding there is “no cause for concern” for the public.Methyl 2-amino-4,5-dimethoxybenzoate vendor In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.
